Cancer treatment can attack healthy tissue while attacking a tumor. This review asks whether proteins from colostrum, the first milk after birth, could help protect the body without weakening treatment. Cancer treatments can be highly effective, but they are also toxic to the patient’s tissues because of how they work.

The immune system, nervous system, gastrointestinal tract, and the body’s normal gut and reproductive-tract microbes are commonly damaged. This toxicity produces adverse side effects in patients undergoing treatment.

The review examines colostrum and colostrum-derived proteins, mainly lactoferrin, as additions to chemotherapy, radiation, hormone treatment, and surgery for cancer, using animal studies and clinical studies. It also discusses a possible protective action seen in laboratory tests and the practical use of these products in clinical care.

Here is the central idea: colostrum components may help repair weakened patients, acting as regenerative agents after drug treatment, radiotherapy, or surgery. The review says these components can protect against treatment complications and help weakened patients recover after drugs, radiation, or surgery.

Used alongside standard drugs, colostrum or its proteins may strengthen treatment effects and allow lower treatment doses, which could further reduce toxicity. In mouse studies, lactoferrin helped restore or normalize an impaired immune response after a drug used to suppress immunity.

In those mice, lactoferrin restored one immune reaction, partly recovered immune-cell growth, and normalized changes in blood-cell composition after treatment. Colostrum and lactoferrin have also been used in clinical care to lessen chemotherapy’s side effects.

In one trial involving people with advanced cancer and anemia, oral lactoferrin was compared with injected iron. Both groups had a significant rise in hemoglobin, with no differences in blood formation, blood iron, or measures of inflammation. Ferritin fell in the lactoferrin group and rose in the ferric-gluconate group, a change that may help avoid harmful iron overload.

In a clinical trial, lactoferrin delivered in a medical food protected people with cancer from diarrhea and low white-cell counts during chemotherapy. Chemotherapy-related diarrhea occurred on fewer days, and both diarrhea reported during medical visits and low white-cell counts were found in a smaller share of patients.

That matters because treatment-related injury to the gut lining is common and can greatly affect quality of life. A separate trial tested daily oral colostrum in children receiving initial chemotherapy for acute lymphoblastic leukemia and experiencing digestive-tract toxicity.

Colostrum did not change fever, antibiotic use, or bloodstream infection, but it lowered the worst level of mouth soreness and the children’s weekly reports of it. The reported result suggests that colostrum may ease mouth inflammation during this chemotherapy, even without changing infection-related problems.

Across animal studies and clinical trials, orally taken colostrum, lactoferrin, and lactoferrin-derived pieces were linked not only with fewer side effects from cancer treatments but also with stronger treatment effects. These effects were reported when colostrum or lactoferrin was used alone and when it was combined with other nutritional products or helpful bacteria.

The review connects these benefits with actions such as supporting immune-cell development, controlling iron use, helping beneficial gut microbes grow, and stabilizing the gut’s protective lining. Its authors recommend including colostrum proteins in cancer treatment plans to improve effectiveness and lessen adverse side effects.

Across animal studies and clinical trials, colostrum and its proteins were linked with fewer treatment side effects and, in some cases, stronger treatment effects. They may become supportive care, not a replacement for cancer therapy.